1
|
Wei Y, Kumar P, Wahome N, Mantis NJ, Middaugh CR. Biomedical Applications of Lumazine Synthase. J Pharm Sci 2018; 107:2283-2296. [DOI: 10.1016/j.xphs.2018.05.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 05/02/2018] [Accepted: 05/02/2018] [Indexed: 10/16/2022]
|
2
|
Azuma Y, Edwardson TGW, Hilvert D. Tailoring lumazine synthase assemblies for bionanotechnology. Chem Soc Rev 2018; 47:3543-3557. [DOI: 10.1039/c8cs00154e] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The cage-forming protein lumazine synthase is readily modified, evolved and assembled with other components.
Collapse
Affiliation(s)
- Yusuke Azuma
- Laboratory of Organic Chemistry
- ETH Zurich
- 8093 Zurich
- Switzerland
| | | | - Donald Hilvert
- Laboratory of Organic Chemistry
- ETH Zurich
- 8093 Zurich
- Switzerland
| |
Collapse
|
3
|
Hiriart Y, Rossi AH, Biedma ME, Errea AJ, Moreno G, Cayet D, Rinaldi J, Blancá B, Sirard JC, Goldbaum F, Berguer P, Rumbo M. Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella. Protein Sci 2017; 26:1049-1059. [PMID: 28257593 DOI: 10.1002/pro.3151] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Revised: 12/09/2016] [Accepted: 02/23/2017] [Indexed: 01/09/2023]
Abstract
Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we generated a chimeric protein (BLS-FliC131) by fusing flagellin from Salmonella in the N-termini of BLS. The obtained protein was recognized by anti-flagellin and anti-BLS antibodies, keeping the oligomerization capacity of BLS, without affecting the folding of the monomeric protein components determined by circular dichroism. Furthermore, the thermal stability of each fusion partner is conserved, indicating that the interactions that participate in its folding are not affected by the genetic fusion. Besides, either in vitro or in vivo using TLR5-deficient animals we could determine that BLS-FliC131 retains the capacity of triggering TLR5. The humoral response against BLS elicited by BLS-FliC131 was stronger than the one elicited by equimolar amounts of BLS + FliC. Since BLS scaffold allows the generation of hetero-decameric structures, we expect that flagellin oligomerization on this protein scaffold will generate a new vaccine platform with enhanced capacity to activate immune responses.
Collapse
Affiliation(s)
- Y Hiriart
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina
| | - A H Rossi
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - M E Biedma
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina
| | - A J Errea
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina
| | - G Moreno
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina
| | - D Cayet
- Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France. Institut National de la Santé et de la Recherche Médicale, U1019, Lille, France. Centre National de la Recherche Scientifique, UMR 8204, Lille, France Université de Lille, Lille, France
| | - J Rinaldi
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - B Blancá
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina
| | - J C Sirard
- Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France. Institut National de la Santé et de la Recherche Médicale, U1019, Lille, France. Centre National de la Recherche Scientifique, UMR 8204, Lille, France Université de Lille, Lille, France
| | - F Goldbaum
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - P Berguer
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - M Rumbo
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina
| |
Collapse
|
4
|
Rossi AH, Farias A, Fernández JE, Bonomi HR, Goldbaum FA, Berguer PM. Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One 2015; 10:e0126827. [PMID: 25973756 PMCID: PMC4431812 DOI: 10.1371/journal.pone.0126827] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Accepted: 04/07/2015] [Indexed: 02/03/2023] Open
Abstract
Brucella Lumazine Synthase (BLS) is a highly immunogenic decameric protein which can accept the fusion of foreign proteins at its ten N-termini. These chimeras are very efficient to elicit systemic and oral immunity without adjuvants. BLS signaling via Toll-Like Receptor 4 (TLR4) regulates innate and adaptive immune responses, inducing dendritic cell maturation and CD8+ T-cell cytotoxicity. In this work we study the effect induced by BLS in TLR4-expressing B16 melanoma. In order to evaluate the effectiveness of BLS as a preventive vaccine, C57BL/6J mice were immunized with BLS or BLS-OVA, and 35 days later were subcutaneously inoculated with B16-OVA melanoma. BLS or BLS-OVA induced a significant inhibition of tumor growth, and 50% of mice immunized with the highest dose of BLS did not develop visible tumors. This effect was not observed in TLR4-deficient mice. For treatment experiments, mice were injected with BLS or BLS-OVA 2 days after the inoculation of B16 cells. Both treatments induced significant and equal tumor growth delay and increased survival. Moreover, BLS and BLS-OVA stimulation were also effective in TLR4-deficient mice. In order to study whether BLS has a direct effect on tumor cells, B16 cells were preincubated with BLS, and after 48h, cells were inoculated. Tumors induced by BLS-stimulated cells had inhibited growth and survival was increased. In the BLS group, 40% of mice did not develop tumors. This effect was abolished by the addition of TLR4/MD2 blocking antibody to cells before BLS stimulation. Our work demonstrates that BLS immunization induces a preventive antitumor response that depends on mice TLR4. We also show that BLS generates a therapeutic effect in mice inoculated with B16 cells. Our results show that BLS acts directly in cultured tumor cells via TLR4, highly suggesting that BLS elicits its therapeutic effects acting on the TLR4 from B16 melanoma cells.
Collapse
Affiliation(s)
- Andrés H. Rossi
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Ana Farias
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Javier E. Fernández
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Hernán R. Bonomi
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Fernando A. Goldbaum
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Paula M. Berguer
- Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- * E-mail:
| |
Collapse
|
5
|
Min J, Kim S, Lee J, Kang S. Lumazine synthase protein cage nanoparticles as modular delivery platforms for targeted drug delivery. RSC Adv 2014. [DOI: 10.1039/c4ra10187a] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Lumazine synthase protein cage nanoparticle is developed as a modular delivery nanoplatform that delivers drugs to their target cancer cells.
Collapse
Affiliation(s)
- Junseon Min
- Department of Biological Sciences
- School of Life Sciences
- Ulsan National Institute of Science and Technology (UNIST)
- Ulsan, Korea
| | - Soohyun Kim
- Department of Biological Sciences
- School of Life Sciences
- Ulsan National Institute of Science and Technology (UNIST)
- Ulsan, Korea
| | - Jisu Lee
- Department of Biological Sciences
- School of Life Sciences
- Ulsan National Institute of Science and Technology (UNIST)
- Ulsan, Korea
| | - Sebyung Kang
- Department of Biological Sciences
- School of Life Sciences
- Ulsan National Institute of Science and Technology (UNIST)
- Ulsan, Korea
| |
Collapse
|
6
|
Sciutto E, Fragoso G, Hernández M, Rosas G, Martínez JJ, Fleury A, Cervantes J, Aluja A, Larralde C. Development of the S3Pvac vaccine against murine Taenia crassiceps cysticercosis: a historical review. J Parasitol 2013; 99:693-702. [PMID: 23409920 DOI: 10.1645/ge-3101.1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Our work of the last 25 yr was concerned with the development of a vaccine aimed to prevent porcine Taenia solium cysticercosis and was based on cross-reacting Taenia crassiceps antigens that had proved protective against experimental intraperitoneal murine T. crassiceps cysticercosis (EIMTcC). In recent times the efficacy of the vaccine has been considered in need of confirmation, and the use of EIMTcC has been questioned as a valid tool in screening for vaccine candidates among the many antigens possibly involved. A review of our work divided in 2 parts is presented at this point, the first dealing with EIMTcC and the second with porcine T. solium cysticercosis (presented in this issue). Herein, we revise our results using EIMTcC as a measure of the protective capacity of T. crassiceps complex antigen mixtures, of purified native antigens, and of S3Pvac anti-cysticercosis vaccine composed by 3 protective peptides: GK-1, KETc1, and KETc12 either synthetic or recombinantly expressed and collectively or separately, by diverse delivery systems when administered at different doses and by different routes. Statistical analyses of the data lead confidently to the strong inference that S3Pvac is indeed an effective vaccine against EIMTcC via specific and non-specific mechanisms of protection.
Collapse
Affiliation(s)
- Edda Sciutto
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México DF, México.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
A polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants. PLoS One 2012; 7:e45705. [PMID: 23029192 PMCID: PMC3454435 DOI: 10.1371/journal.pone.0045705] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Accepted: 08/22/2012] [Indexed: 11/19/2022] Open
Abstract
Lumazine synthase from Brucella spp. (BLS) is a highly immunogenic decameric protein. It is possible to insert foreign peptides or proteins at its ten-amino acid termini. These chimeras elicit systemic and oral immunity without adjuvants, which are commonly needed in the formulation of subunit-based vaccines. Here, we show that BLS induces the cross presentation of a covalently attached peptide OVA257–264 and a specific cytotoxic response to this peptide in the absence of adjuvants. Unlike other subunit-based vaccines, this chimera induces rapid activation of CTLs and a specific cytotoxic response, making this polymeric protein an ideal antigen carrier for vaccine development. Adoptive transfer of transgenic OT-I T cells revealed efficient cross presentation of BLS-OVA257–264in vivo. BLS-OVA257–264 immunization induced the proliferation of OVA257–264-specific CD8+ lymphocytes and also increased the percentage of OVA257–264-specific CD8+ cells expressing the early activation marker CD69; after 5 days, the percentage of OVA257–264-specific CD8+ cells expressing high levels of CD44 increased. This cell subpopulation showed decreased expression of IL-7Rα, indicating that BLS-OVA257–264 induced the generation of CD8+ effector cells. BLS-OVA257–264 was cross presented in vitro independently of the presence of a functional TLR4 in the DCs. Finally, we show that immunization of wild type mice with the chimera BLS-OVA257–264 without adjuvants induced a strong OVA257–264-specific effector cytotoxic response. This cytotoxicity is dependent on TLR4 as is not induced in mice lacking a functional receptor. These data show that TLR4 signaling is necesary for the induction of a cytotoxic response but not for antigen cross presentation.
Collapse
|
8
|
Lightowlers MW. Fact or hypothesis: Taenia crassiceps as a model for Taenia solium, and the S3Pvac vaccine. Parasite Immunol 2011; 32:701-9. [PMID: 21039610 PMCID: PMC3033518 DOI: 10.1111/j.1365-3024.2010.01231.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Research undertaken over the past 40 years has established many of the general principals concerning immunity to taeniid cestodes. Although much is well understood about the host-protective mechanisms against taeniids and this knowledge has been exploited in studies on vaccine development, many aspects require further investigation or confirmation. Some phenomena have come to be regarded as being well established, while careful analysis of the published data would suggest that they may be better regarded as hypotheses rather than established facts. This review considers one selected issue pertaining to immunity to cestode infections and examines carefully the nature of the evidence that is available to support conclusions that have been made in this area. The issue examined is the use of Taenia crassiceps as a model for cysticercosis in pigs caused by Taenia solium, together with the S3Pvac vaccine, which has been developed based on this model. Strong evidence is found to support the conclusion that defined T. crassiceps antigens can limit intraperitoneal proliferation of the ORF strain of T. crassiceps in mice; however, the potential for these antigens to affect T. solium infection in pigs requires further confirmation.
Collapse
Affiliation(s)
- M W Lightowlers
- Faculty of Veterinary Science, The University of Melbourne, Werribee, Vic., Australia.
| |
Collapse
|
9
|
Ainciart N, Zylberman V, Craig P, Nygaard D, Bonomi H, Cauerhff A, Goldbaum F. Sensing the dissociation of a polymeric enzyme by means of an engineered intrinsic probe. Proteins 2011; 79:1079-88. [DOI: 10.1002/prot.22945] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Revised: 10/29/2010] [Accepted: 11/07/2010] [Indexed: 01/09/2023]
|
10
|
Protection of mice from Brucella infection by immunization with attenuated Salmonellaenterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine 2009; 27:5214-9. [DOI: 10.1016/j.vaccine.2009.06.075] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2009] [Revised: 06/21/2009] [Accepted: 06/22/2009] [Indexed: 11/19/2022]
|
11
|
Bellido D, Craig PO, Mozgovoj MV, Gonzalez DD, Wigdorovitz A, Goldbaum FA, Dus Santos MJ. Brucella spp. lumazine synthase as a bovine rotavirus antigen delivery system. Vaccine 2009; 27:136-45. [DOI: 10.1016/j.vaccine.2008.10.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2008] [Revised: 09/30/2008] [Accepted: 10/02/2008] [Indexed: 11/29/2022]
|
12
|
Sciutto E, Rosas G, Hernández M, Morales J, Cruz-Revilla C, Toledo A, Manoutcharian K, Gevorkian G, Blancas A, Acero G, Hernández B, Cervantes J, Bobes RJ, Goldbaum FA, Huerta M, Diaz-Orea A, Fleury A, de Aluja AS, Cabrera-Ponce JL, Herrera-Estrella L, Fragoso G, Larralde C. Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine. Vaccine 2006; 25:1368-78. [PMID: 17188784 DOI: 10.1016/j.vaccine.2006.10.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2006] [Revised: 10/03/2006] [Accepted: 10/04/2006] [Indexed: 11/29/2022]
Abstract
Vaccination of pigs may curtail Taenia solium transmission by reducing the number of cysticerci, the precursors of adult intestinal tapeworms in humans. Several antigen preparations induce protection against porcine cysticercosis in experimental settings but only one subunit vaccine (S3Pvac) has been tested and proved effective in the field against naturally acquired disease. Besides improving of the vaccine's effectiveness, significant reductions in production costs and in the logistics of its administration are necessary for the feasibility of nationwide control programs. This review highlights the development of several versions of S3Pvac aimed to increase effectiveness, reduce costs and increase feasibility by novel delivery systems and alternative routes of administration.
Collapse
Affiliation(s)
- Edda Sciutto
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México, D.F. 04510, Mexico.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Cruz-Revilla C, Toledo A, Rosas G, Huerta M, Flores-Perez I, Peña N, Morales J, Cisneros-Quiñones J, Meneses G, Díaz-Orea A, Anciart N, Goldbaum F, Aluja A, Larralde C, Fragoso G, Sciutto E. Effective Protection Against Experimental Taenia solium Tapeworm Infection in Hamsters by Primo-Infection and by Vaccination with Recombinant or Synthetic Heterologous Antigens. J Parasitol 2006; 92:864-7. [PMID: 16995407 DOI: 10.1645/ge-779r1.1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The disease caused by Taenia solium is progressively being recognized as a growing global threat for public human health and pig husbandry that requires the development of effective control measures. A central participant in the taeniasis/cysticercosis transmission network is the human carrier of the adult tapeworm because of its great potential in spreading the infection. Herein, evidence is presented that a primary infection of golden hamsters with orally administered T. solium cysticerci improved the host's resistance against a secondary infection. Likewise, previous vaccination increased the hamster's resistance. Similar high levels of protection (> 78%) were induced by systemic or oral vaccination with the S3Pvac anticysticercosis synthetic peptide vaccine or the highly immunogenic recombinant chimera based on the protective peptide KETc1 bound to Brucella spp. lumazine synthase (BLS-KETc1). Increased resistance after primo-infection and vaccination possibly results from changes in the immune conditions prevailing in the host's intestine. The contribution to protection from the KETc1 and BLS epitopes in a chimeric vaccine is under study. Preventive vaccination of definitive hosts of T. solium against the tapeworm, the most relevant step in the taeniasis/cysticercosis transmission, may greatly impact the dynamics of endemic disease and has not been studied or tried previously.
Collapse
Affiliation(s)
- C Cruz-Revilla
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, A.P. 70228, México D.F. C.P. 04510, México
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Craig PO, Berguer PM, Ainciart N, Zylberman V, Thomas MG, Martinez Tosar LJ, Bulloj A, Boccaccio GL, Goldbaum FA. Multiple display of a protein domain on a bacterial polymeric scaffold. Proteins 2006; 61:1089-100. [PMID: 16193482 DOI: 10.1002/prot.20635] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The multiple display of protein domains on polymeric scaffolds is an emerging technology for many applications. BLS is a highly immunogenic protein that has an oligomeric structure formed by a 17.2 kDa subunit arranged as a dimer of pentamers. Here we describe the production as well as the structural, functional, and immunological properties of a 9 kDa double-stranded RNA-binding domain (RBD3) fused to the structure of BLS. We demonstrate that the BLS and RBD3 modules are stably and independently folded in the structure of the chimera and form a decameric structure of 255 kDa as the native BLS oligomers. The polymeric display of RBD3 in the structure of BLS increases the dsRNA binding strength of this domain both in vitro and in vivo, and also enhances its immunogenicity to the point that it breaks the tolerance of mice to the RBD3 self-antigen. Our results underscore the BLS display strategy as a powerful tool for biotechnological and therapeutic applications.
Collapse
Affiliation(s)
- P O Craig
- Fundación Instituto Leloir, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Rosas G, Fragoso G, Ainciart N, Esquivel-Guadarrama F, Santana A, Bobes RJ, Ramírez-Pliego O, Toledo A, Cruz-Revilla C, Meneses G, Berguer P, Goldbaum FA, Sciutto E. Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes Infect 2006; 8:1277-86. [PMID: 16697684 DOI: 10.1016/j.micinf.2005.12.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2005] [Revised: 12/07/2005] [Accepted: 12/08/2005] [Indexed: 12/13/2022]
Abstract
Brucella lumazine synthase (BLS) has been previously used with success as a delivery system for systemic immunization against murine cysticercosis. We herein determined the usefulness of BLS as a new antigen-delivery system and mucosal-adjuvant using KETc1, one of the peptides of the anti-cysticercosis vaccine. A protection of up to 98% was induced when KETc1 was used as a chimera fused to BLS. Used as adjuvant of KETc1, BLS also induced a high level of protection (79%), which did not significantly differ from that induced by the cholera toxin (74%). KETc1 and BLS administered separately also reduced the parasite load. KETc1 administered orally as a chimera, and to a lesser extent with BLS as adjuvant, elicited IgG and IgA specific antibodies, which were detectable both in fecal extracts and in sera, and increased B and CD4 activated cells. BLS-KETc1 also increased the levels of transcription of TNF-alpha, IL-2 and IFNgamma in Peyer's patches, and in spleen, only increased TNF-alpha was observed. Overall, these results showed that BLS can be used as both an antigen-carrier and as an adjuvant in the design of new oral subunit vaccines.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Administration, Oral
- Animals
- Antibodies, Helminth/blood
- Antigens, Helminth/administration & dosage
- Antigens, Helminth/chemistry
- Antigens, Helminth/genetics
- Antigens, Helminth/immunology
- Brucella/enzymology
- Cysticercosis/immunology
- Cysticercosis/prevention & control
- Cytokines/metabolism
- Female
- Humans
- Immunity, Mucosal
- Mice
- Mice, Inbred BALB C
- Multienzyme Complexes
- Peyer's Patches/immunology
- Recombinant Fusion Proteins/administration & dosage
- Recombinant Fusion Proteins/immunology
- Taenia/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- Gabriela Rosas
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos, 62210 Cuernavaca, Morelos, México
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Berguer PM, Mundiñano J, Piazzon I, Goldbaum FA. A Polymeric Bacterial Protein Activates Dendritic Cells via TLR4. THE JOURNAL OF IMMUNOLOGY 2006; 176:2366-72. [PMID: 16455994 DOI: 10.4049/jimmunol.176.4.2366] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The enzyme lumazine synthase from Brucella spp. (BLS) is a highly immunogenic protein that folds as a stable dimer of pentamers. It is possible to insert foreign peptides and proteins at the 10 N terminus of BLS without disrupting its general folding, and these chimeras are very efficient to elicit systemic and oral immunity without adjuvants. In this study, we show that BLS stimulates bone marrow dendritic cells from mice in vitro to up-regulate the levels of costimulatory molecules (CD40, CD80, and CD86) and major histocompatibility class II Ag. Furthermore, the mRNA levels of several chemokines are increased, and proinflammatory cytokine secretion is induced upon exposure to BLS. In vivo, BLS increases the number of dendritic cells and their expression of CD62L in the draining lymph node. All of the observed effects are dependent on TLR4, and clearly independent of LPS contamination. The described characteristics of BLS make this protein an excellent candidate for vaccine development.
Collapse
Affiliation(s)
- Paula M Berguer
- Fundación Instituto Leloir, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | | | | | | |
Collapse
|